C.?The Association for the Accreditation of Human Research Protection Programs Inc. today announced that it has awarded accreditation to four additional organizations, including one more in Korea.
The Association for the Accreditation of Human Research Protection Programs Inc
. today announced that it has awarded accreditation to four additional organizations, including one more in Korea. The newly accredited organizations are:
The accreditations are the latest example of AAHRPP’s continued growth throughout the research enterprise. They also reflect AAHRPP’s steady progress in achieving the goal of one standard worldwide for protecting research participants and advancing high-quality research.
“These accreditations underscore that AAHRPP’s standards apply equally well to organizations across the research spectrum,” said Marjorie A. Speers, Ph.D., AAHRPP president and CEO. “AAHRPP accreditation is widely regarded as the mark of a quality human research protection program worldwide.”
AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Korea, Mexico, Singapore and Taiwan.
Since its founding in 2001, AAHRPP has been instrumental in persuading research organizations to focus on quality improvement and routinely assess their performance. As a result, today’s AAHRPP-accredited HRPPs can point to measurable improvements in advancing research, protecting participants and building public trust.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.